USA – FDA issues final guidance on rare disease drug development
The US Food and Drug Administration (FDA) finalized guidance on drug development programs for rare diseases, eliminating a section on natural history and providing...
USA – Novel Drug Approvals for 2023
Innovative drugs often mean new treatment options for patients and advances in health care for the American public. When it comes the development of...
USA – Industry groups seek changes to FDA’s remote interactive evaluation guidance
Trade groups representing the pharmaceutical and clinical research industries endorsed the US Food and Drug Administration’s (FDA) approach for conducting remote interactive evaluations (RIE)...
USA – FDA CGT draft guidance focuses on potency assurance strategy
The US Food and Drug Administration has proposed a guidance that would update its policy on how sponsors can provide information on potency assurance...
USA – FDA adds microbiological assessments to ophthalmic drug quality guidance
The US Food and Drug Administration (FDA) recently issued a revised draft guidance for topical ophthalmic drugs recommending that manufacturers follow certain microbial testing...
USA – FDA issues final guidance on major statement in DTC ads
The US Food and Drug Administration (FDA) last week published a final guidance detailing five standards drug manufacturers should follow to ensure direct-to-consumer (DTC)...
USA – FDA finalizes guidance to limit use of benzene in drug products
The US Food and Drug Administration (FDA) recently finalized a guidance to expedite the reformulation of drug products that use inactive ingredients manufactured with...
Canada – Notice – Implementation of ICH E19: A selective approach to safety data...
Health Canada, as an official member to the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), is committed to...
USA – FDA proposes master control trial guidance that goes beyond COVID-19
The US Food and Drug Administration (FDA) this week published a draft guidance on the use of master protocols in clinical trials of drugs...
USA – Stakeholders concerned with FDA’s definition of labeling in PDURS guidance
Stakeholders want the US Food and Drug Administration (FDA) to narrow its scope of what it considers labeling in a draft guidance for prescription...
